

ASX ANNOUNCEMENT

# Change of Company Name, ASX Code and Registered Office

Wednesday, 8 July 2026

## Change of Company Name

Following shareholder approval at the Extraordinary General Meeting held on 3 July 2026, Ceryvyn Therapeutics Ltd (ASX:CYV) (formerly Opthea Ltd) (“Ceryvyn” or “the Company”) is pleased to advise the Company’s name change has been processed by the Australian Securities and Investment Commission (ASIC).

Ceryvyn shares will trade with the ASX code ‘CYV’, effective from the commencement of trading on Thursday, 9 July 2026.

The Company’s website address has been updated to [www.ceryvyn.com](http://www.ceryvyn.com).

## Change of Registered Office

In accordance with ASX Listing Rule 3.14, with effect today, the Company advises that its registered office and principal place of business will change to:

C/- Bio101 Financial Advisory Pty Ltd  
Suite 1.01  
117 Camberwell Road  
Hawthorn East VIC 3123

This announcement was authorised for release by the Board of Ceryvyn Therapeutics Ltd.

## About Ceryvyn Therapeutics (ASX: CYV)

Ceryvyn Therapeutics Ltd (ASX: CYV) is a clinical-stage biopharmaceutical company developing innovative therapies by translating advances in human biology into transformative medicines for patients with serious diseases. The Company seeks to identify biological mechanisms that drive disease and develop targeted therapies capable of addressing significant unmet medical need.

Ceryvyn's current focus is lymphangioliomyomatosis (LAM) - a rare, chronic and progressive systemic disease that predominantly affects women and primarily involves the lungs, where it leads to progressive loss of lung function. Despite currently available therapies, there remains no cure and significant unmet medical need.

The Company's lead development program, CYV-101, is a first-in-class fusion protein designed to selectively bind and neutralise VEGF-C and VEGF-D, key signalling proteins involved in pathological lymphangiogenesis. By targeting a fundamental biological pathway believed to drive disease progression, CYV-101 has the potential to offer a differentiated therapeutic approach for patients with LAM.

Ceryvyn is committed to building a biotechnology company grounded in scientific excellence, rigorous clinical development and a relentless focus on improving the lives of patients while creating sustainable long-term value for shareholders.

To learn more, visit our website as [www.ceryvyn.com](http://www.ceryvyn.com) and follow us on [LinkedIn](#).

## Contact

Ryan Thompson

+61 423 151 378

[ryan.thompson@sodali.com](mailto:ryan.thompson@sodali.com)